The cardioprotective effects of an mAb to P-selectin designated mAb PB1.3 was examined in a feline model of myocardial ischemia (MI) and reperfusion. PB1.3 (1 mg/kg), administered after 80 min of ischemia (i.e., 10 min before reperfusion), significantly attenuated myocardial necrosis compared to a nonblocking mAb (NBP1.6) for P-selectin (15±3 vs 35±3% of area at risk, P < 0.01). Moreover, endothelial release of endothelium derived relaxing factor, as assessed by relaxation to acetylcholine, was also significantly preserved in ischemic-reperfused coronary arteries isolated from cats treated with mAb PB1.3 compared to mAb NBP1.6 (67±6 vs 11±3, P < 0.01). This endothelial preservation was directly related to reduced endothelial adherence of PMNs in ischemic-reperfused coronary arteries. Immunohistochemical localization of P-selectin was significantly upregulated in the cytoplasm of endothelial cells that lined coronary arteries and veins after 90 min of ischemia and 20 min of reperfusion. The principal site of intracytoplasmic expression was in venous vessels. mAb PB1.3 significantly decreased (P < 0.01 ) adherence of unstimulated PMNs to thrombin and histamine stimulated endothelial cells in a concentration-dependent manner in vitro. These results demonstrate that PMN adherence to endothelium by P-selectin is an important early consequence of reperfusion injury, and a specific monoclonal antibody to P-selectin exerts significant endothelial preservation and cardioprotection in myocardial ischemia and reperfusion. (J. Clin. Invest. 1993. 91:2620-2629 
Introduction
The proximity of the endothelium to circulating leukocytes makes it an important early target for neutrophil adherence and subsequent PMN-mediated damage ( ). This adhesive interaction can be rapidly induced and is characterized by the expression of adhesion molecules such as P-selectin on the endothelial surface (2) . P-selectin, also known as granule membrane protein-140, is an integral membrane glycoprotein located in platelets and in Weibel-Palade bodies of endothelial cells (3) . Upon activation of the endothelium with agonists such as thrombin and histamine, the Weibel-Palade bodies fuse with the plasma membrane, and P-selectin is rapidly translocated to the endothelial cell surface in 5 5 min, where it tethers circulating PMNs and positions them foractivation by endothelial-bound platelet activating factor (3, 4) .
This adhesive interaction between PMNs and endothelial cells is an early and requisite event in inflammatory disorders such as ischemia reperfusion injury (5, 6) . Ischemia followed by reperfusion is also associated with a decrease in agonist-stimulated (7) and basal nitric oxide (NO) (8) release, which has also been shown to increase PMN adherence to endothelial cells (9) . Moreover, this burst of free radical generation at the onset ofreperfusion coincides with a marked reduction in endothelium-derived relaxing factor (EDRF) l (7) and precedes the induction ofP-selectin expression on endothelial cells ( 10, 11 ).
Thus, rapid expression ofP-selectin on endothelial cells may be responsible, at least in part, for the initial cascade of PMN-mediated effects that ultimately results in myocardial tissue injury after ischemia reperfusion. However, in vivo studies have not addressed the role of P-selectin in regulating PMN recruitment in an ischemic-reperfusion setting. Therefore, the purposes of this study were (a) to determine the effect of a monoclonal antibody to P-selectin on myocardial tissue injury associated with ischemia and reperfusion in cats; (b) to relate the myocardial injury to endothelial dysfunction and adherence of PMNs to the coronary vascular endothelium; and (c) to examine P-selectin expression by endothelial cells after ischemia and reperfusion and determine how this relates to PMN-endothelial interactions associated with reperfusion injury.
Methods
Monoclonal antibodies. mAbs PBI.3 (also known as Cy-1747) and NBP1.6 are murine IgG, monoclonal antibodies raised against human P-selectin, which were obtained from Cytel Corp. (San Diego, CA). PB 1.3 blocks the interaction between P-selectin and the sialyl Lewis X ligand while NBP1.6 does not block the interaction between P-selectin and the sialyl Lewis X ligand although it recognizes P-selectin. The complete characterization of these antibodies is previously described ( 12) .
Experimental protocol. Adult male cats (2.6-3.4 kg) were anesthetized intravenously with sodium pentobarbital (30 mg/kg). An intratracheal cannula was inserted through a midline incision, and all cats were placed on intermittent positive-pressure ventilation (small ani-mal respirator; Harvard Apparatus, Dover, MA). A polyethylene catheter was inserted into the right external jugular vein for supplementary pentobarbital infusion to maintain a surgical plane of anesthesia and for administration of antibodies. An additional polyethylene catheter was inserted through the left femoral artery and positioned in the abdominal aorta for measurement of mean arterial blood pressure (MABP) via a pressure transducer (Statham P23AC; Gould, Inc., Cleveland, OH). After a midsternal thoracotomy, the pericardium was incised and a 3-0 silk ligature was placed around the left anterior descending (LAD) coronary artery 8-10 mm from its origin. Standard lead II of the scalar electrocardiogram (ECG) was used to determine heart rate (HR) and ST segment elevation. ST segment elevations were determined by analysis of an ECG recording at 50 mm/s every 20 min. The ECG and MABP were continuously recorded on an oscillographic recorder (model 7; Grass Instrument Co., Quincy, MA), and the pressure-rate index (PRI), an approximation of myocardial oxygen demand, was calculated as the product of MABP and HR divided by 1,000.
After completing all surgical procedures, the cats were allowed to stabilize for 30 Myocardial tissue analysis. At the end of the 270-min postreperfusion period, the ligature around the LAD was retightened. 20 ml of 0.5% Evans blue was injected over a period of 1 min into the left ventricle to stain the area of myocardium that was perfused by the patent coronary arteries. The area at risk was thus determined by negative staining. Immediately after this injection, the heart was rapidly excised and placed in warmed, oxygenated Krebs-Henseleit (K-H) buffer consisting of (in mM): NaCl, 118; KCl, 4.75; CaC12 2-2H20, 2.54; KH2PO4, 1.19; MgSO4-7H20, 1.19; NaHCO3, 12.5, and glucose, 10.0.
The left circumflex (LCX) and the LAD coronary arteries were isolated and removed for subsequent study of coronary ring vasoactivity. The right ventricle and great vessels were then carefully removed, and the left ventricle was sliced parallel to the atrioventricular groove in 3-mm thick sections according to previously reported methods (7) . The unstained portion of the myocardium (i.e., the total area at risk) was separated from the Evans blue-stained portion ofthe myocardium (i.e., the area not at risk). The area at risk was again sectioned into 1-mm thick slices and incubated in 0.1% nitroblue tetrazolium in phosphate buffer at pH 7.4 and 37°C for 15 min. The tetrazolium dye forms a blue formazan complex in the presence ofcoenzymes and dehydrogenases. The irreversibly injured or necrotic portion of the myocardium at risk that did not stain was separated from the stained portion of the myocardium (i.e., the ischemic but nonnecrotic area). The nonischemic, ischemic nonnecrotic, and ischemic necrotic tissues were subsequently weighed and the results were expressed as the area at risk indexed to the total left ventricular mass, the area of necrotic tissue indexed to the area at risk, and the area of necrotic tissue indexed to the total left ventricular mass. In three additional cats receiving only 0.9% NaCl as a vehicle, the above procedures were repeated, except that half of the area at risk was incubated with 20 ,g/ ml of mAb PB 1.3 These values are not significantly different indicating that mAb PB 1.3 had no effect on nitroblue tetrazolium staining properties.
Isolated coronary ring studies. Both LAD and LCX coronary segments were removed and placed into warmed K-H buffer. Isolated coronary vessels were cleaned and cut into rings 2-3 mm in length. The rings were then mounted on stainless steel hooks, suspended in 10-ml tissue baths, and connected to force displacement transducers (FT-03; Grass Instrument Co.) to record changes in force on an oscillographic recorder (model 7; Grass Instrument Co.). The baths were filled with 10 ml of K-H buffer and aerated at 370C with a gas mixture of 95% 02 and 5% CO2. Coronary rings were initially stretched to give a preload of 0.5 g of force and equilibrated for 60-90 min. During this period, the K-H buffer in the tissue baths was replaced every 15 min. After equilibration, the rings were then exposed to 100 nM U-466 19 (9,1 1-epoxymethano-PGH2; Biomol Research Laboratories, Plymouth Meeting, PA), a thromboxane A2 mimetic, to generate about 0.5 g of developed force. Once a stable contraction was obtained, acetylcholine (ACh), an endothelium-dependent vasodilator, was added to the bath in cumulative concentrations of0.1, 1, 10, and 100 nM. After the response stabilized, the rings were washed and allowed to equilibrate to baseline once again. The procedure was repeated with another endothelium-dependent vasodilator, A-23187, (1, 10, 100, and 1,000 nM), and then again with an endothelium-independent vasodilator, acidified NaNO2, (0.1, 1, 10, and 100 uM), at pH 2.
Cat PMN isolation and labeling. In six MI + R cats, peripheral blood ( 10 ml) was collected from the femoral artery before the onset of ischemia reperfusion and anticoagulated with citrate-phosphate-dextrose solution (Sigma Immunochemicals, St. Louis, MO) ( 1.4:10 vol/ vol anticoagulant to whole blood). 20 ml of 0.9% NaCI was immediately infused to replace the blood volume and the cats were allowed to stabilize for 30 min. The blood was placed into round-bottom polycarbonate centrifuge tubes (Nalge, Rochester, NY) and PMNs were isolated by a procedure modified from Lafredo and Olsen ( 13) . Plateletrich plasma (PRP) was obtained by centrifuging blood at 400 g for 20 min (Econospin tabletop swinging bucket centrifuge; Sorvall Instruments, Wilmington, DE). PRP was decanted and centrifuged at 2,500 g for 10 min to obtain platelet-poor plasma (PPP). PPP was then mixed with isotonic Percoll (Sigma Immunochemicals) (9 vol Percoll/ 1 vol 1.5 M NaCI) to produce Percoll-PPP density gradients of 80, 62, and 50%. 8 ml of 6% dextran (average mol wt 60,000-90,000, Sigma, St. Louis, MO) and 20 ml of PBS were added to the erythrocyte-leukocyte pellet from the initial 400 gcentrifugation. After mixture by inversion, the erythrocytes were allowed to settle for 40-60 min. The leukocyte enriched fraction was resuspended in 1 ml of 0.9% NaCI and layered onto the Percoll/PPP gradient. The suspensions were then centrifuged at 1,000 g for 40 min at 4°C in a refrigerated centrifuge (RC2-B; Sorvall Instruments, Newtown, CT). PMNs were collected from the 62-82% interface and washed twice with PBS before being assayed for viability using trypan blue exclusion. PMN and three cats received mAb NBP1.6) and the ischemic-reperfused LAD and control LCX coronary segments were isolated and removed as previously described ( 15) . The arteries were opened and placed into the cell culture dishes containing 3 ml of K-H buffer. Autologously labeled PMNs (400,000 PMNs/ml) were then added to the arteries and allowed to incubate for 20 min in a metabolic shaker bath at 370C. The arteries were removed and PMN adherence to coronary artery endothelium was counted using fluorescence microscopy as previously described (8) . The number of PMNs were counted in duplicate and reported as PMN per square millimeter of the coronary endothelial surface.
Effect ofmAb PBJ.3 on unstimulatedPMNadherence to stimulated coronary artery endothelium. In six additional cats, peripheral blood (80 ml) was collected from the femoral artery and anticoagulated with citrate-phosphate-dextrose solution. PMNs were isolated as described above. Hearts from each control cat were removed and placed in warm oxygenated K-H buffer. Both the LAD and LCX coronary arteries were removed and cut in 2-3-mm segments. The arteries were then opened, and placed into a cell culture dish filled with 3 ml of K-H buffer. To stimulate endothelial cells, the coronary rings were incubated for 10 min with either 2 U /ml ofthrombin (Sigma Immunochemicals) or 10 MgM histamine (Sigma Immunochemicals). After this 10 min incubation period, the coronary ring segments were removed and placed in fresh K-H solution. In the first series, labeled PMNs (400,000 PMNs/ ml) were added to thrombin-stimulated endothelial cells alone and in combination with increasing concentrations of mAb PB 1.3 (5, 10, 20, 30 , and 40 ,g/ml). In the second series, labeled PMNs were added concomitantly with 20 ,g/ ml ofmAb PB 1.3 to endothelial cells stimulated with either thrombin or histamine. After 20 min, the coronary rings were removed and adherent PMNs were counted using fluorescence microscopy as described above.
Effect ofmAb PBJ.3 on unstimulated PMN adherence to ischemicreperfused coronary artery endothelium. In three additional cats that were subjected to 90 min of ischemia and 20 min of reperfusion, ischemic-reperfused LAD and nonischemic LCX coronary artery segments were removed and prepared for PMN adherence studies as previously described. The rings were placed in the cell culture dishes and unstimulated PMNs (400,000 PMNs/ml) were added simultaneously with either 20 ug/ml ofmAb PB 1.3 or mAb NBP1.6 for 20 min in a metabolic shaker bath at 370C. Coronary artery segments were then removed from the culture dishes and PMN adherence to the endothelium was assessed as described above.
Immunohistochemical localization of P-selectin. To assess the cross-reactivity of mAb PB 1.3 with feline endothelium, three cats were exposed to 90 min of ischemia followed by 20 min of reperfusion, and two cats were exposed to 90 min of ischemia followed by 270 min of reperfusion. The hearts were subsequently removed and the aorta was immediately cannulated and perfused with K-H solution for 2 min at 50 mmHg. After this 2 min washout period, the K-H solution was switched to 4% paraformaldehyde in PBS and the hearts were perfusion fixed for 5 min. Full thickness slices of the left ventricular wall ( 1 mm in thickness and 5 mm in width) were fixed for 2 h at 40C. Slices, cut from the ischemic-reperfused region and the nonischemic region, were dehydrated in a graded series of acetone at 4VC and embedded (Immunobed; Polysciences Inc., Warrington, PA) at 4VC for 12 h. 5-,gm thick sections were cut using glass knives and transferred to coated slides (Vectabond; Vector Laboratories, Burlingame, CA).
Immunohistochemical procedures on plastic sections were performed in the following sequence using a modification ofthe methods described previously by Beckstead et al. ( 16) using the avidin-biotin immunoperoxidase technique (Vectastain ABC Reagent; Vector Laboratories). Incubation of the primary antibody was carried out overnight at room temperature at dilutions of 1: 100, 1: 1,000, and 1:2,000 in PBS. Control preparations for immunohistochemistry included omission of the primary antibody and also incubation with the primary antibody but with omission of the secondary antibody (biotinylated IgG). The sections were examined using a Zeiss microscope.
Flow cytometric analysis ofbinding ofPBJ.3 to cat platelets. The binding of the mAb PBl .3 to freshly isolated cat platelets was determined by flow cytometric analysis. Briefly, peripheral arterial blood was collected from the femoral artery of four pentobarbital-anesthetized cats and was anticoagulated with 3.8% sodium citrate. The blood was placed into round-bottom polycarbonate centrifuge tubes and PRP was obtained by centrifuging the blood at 400 g for 20 min. The PRP was removed and recentrifuged at 2,500 g to form a platelet pellet. The platelet pellet was washed twice in calcium-free Tyrode's solution containing 1% BSA. Platelets were resuspended in Dulbecco's PBS and 0.2% BSA and aliquots of 2 X 108 platelets/ml were activated with human thrombin (Sigma Immunochemicals) at 0.25 U/ml for 20 min at room temperature in the presence of4 mM Ca2+ . After the thrombin incubation period, EDTA was added to the cell suspensions at a final concentration of 10 mM, and the cell suspensions were centrifuged (Eppendorf microcentrifuge; Brinkman Instruments, Westbury, NY) for 30 s at 7,000 rpm, and the supernatant was discarded. The platelets were then washed in PBS containing 10 mM EDTA and centrifuged. Additional aliquots of platelets were treated in an identical manner with the exception ofthe thrombin treatment, and these platelet suspensions served as controls for these experiments. The platelet suspensions were treated with human block IgG (4.0 mg/ml) (Sigma Immunochemicals), and then PB 1.3 (40 Mg/ml) or human IgG, (Coulter, Hialeah, FL) (40 Mg/ml) was added to the cat platelets. The platelets were incubated at room temperature for 30 min. The platelets were then washed in Dulbecco's PBS to remove any excess ofthe primary antibodies. F(ab')2 fragments of a goat anti-mouse IgG-phycoerythrin conjugate (Tago, Inc., Burlingame, CA) was used as the secondary antibody reagent at a 1:100 dilution and the cells were placed on ice for 30 min. The stained platelets were then washed and fixed in 1.0% paraformaldehyde and then analyzed on a flow cytometer (EPICS; Coulter, Hialeah, FL). Platelet aggregation. Aggregation studies were performed on cat platelets that were washed as previously described. Platelets were aggregated with 0.1 U/ml of thrombin in the presence or absence of PB1.3 MAg/ml), NBP1.6 (20-40 Mg/ml), or 40 ng/ml of taprostene (i.e., a stable prostacyclin analog) (17) . AU aggregation studies were conducted in duplicate, and the results were expressed as a percentage of maximal aggregation (100% light transmittance).
Statistical analysis. All values in the text, table, and figures are presented as means±SEM ofn independent experiments. All data were subjected to ANOVA followed by the Bonferroni correction for posthoc t test. P . 0.05 or less were considered to be statistically significant.
Results
Immunohistochemical localization ofP-selectin. Coronary endothelial P-selectin was detected by using PB 1.3 with a sensitive avidin-biotin immunoperoxidase procedure applied to 5-,um thick plastic-embedded sections ofheart tissue. The immunohistochemical results are illustrated in Fig. 1 . Nonischemic (control) tissue demonstrated faint patchy cytoplasmic immunostaining primarily ofthe endothelial cells that lined coronary venules (Fig. 1 A) . Occasional weak cytoplasmic staining was demonstrated by endothelial cells lining epicardial arteries and veins. However, no cytoplasmic staining was observed on coronary capillary endothelium. Negative control immunohistochemical preparations, in which either the primary antibody (PB 1.3; Fig. 1 B) or the biotinylated secondary antibody (VectaStain Elite mouse IgG; Fig. 1 C) was replaced by nonimmune serum, did not label endothelial cells. On the other hand, endothelial cell P-selectin was evident in ischemic-reperfused heart tissue when the nonblocking antibody NBP1.6 was applied (Fig. 1 D) and when mAb PB1.3 was used (Fig. 1 E) Fig. 1 F) . Most of the venules had abundant cytoplasmic staining. P-selectin was also detected in arteries and arterioles, although the reaction product was usually patchy and less intense than for venules. Capillary endothelium showed a patchy distribution. Some capillaries were immunoperoxidase-positive while others were not. In other Effect ofmAb PBI.3 on reperfusion myocardial injury. To ascertain the effects ofmAb PB 1.3 on the degree ofactual myocardial salvage of ischemic tissue after reperfusion, we used an anatomic measurement of necrotic tissue as an index of ischemia reperfusion injury. The wet weights of the areas of myocardium subjected to ischemia (i.e., the area at risk) expressed as a percentage of the total left ventricular weights were not significantly different between the two MI + R groups (Fig. 2) , further confirming that the severity of the ischemic insult was comparable in both ischemic groups. In contrast, the mass of the necrotic myocardial tissue expressed as a percentage of the mass of the myocardial area at risk was significantly less in the mAb PB 1.3-treated group. About 35% ofthe jeopardized myocardium developed into necrotic tissue in the MI + R mAb NBP1.6 group, whereas only 15% of the area at risk became necrotic in the mAb PB 1 .3 group (P < 0.01 In vivo administration ofmAb PBI.3 inhibitedPMNadherence to ischemia reperfused coronary endothelium ex vivo. An early step in neutrophil-mediated injury is the increased adhesion of neutrophils to the vascular endothelium. In this study, we observed the effects of in vivo administered mAb PB 1.3 on autologous unstimulated PMN adherence to ischemic-reperfused coronary endothelium (i.e., 90 min ischemia and 270 min reperfusion). When unstimulated PMNs were added alone to non-ischemic-reperfused control LCX coronary arteries and incubated for 20 min, few neutrophils adhered to the endothelial surface. However, when unstimulated PMNs were added to LAD coronary arteries isolated 270 min after reperfusion from cats receiving mAb NBP1.6 and incubated for 20 min, a dramatic increase in PMN adherence was observed (Fig.  4) . In contrast, when unstimulated PMNs were added to the ischemia reperfused LAD coronary arteries isolated from the cats treated with mAb PB 1.3, the number ofPMNs adhering to the coronary endothelium was significantly reduced (Fig. 4) . Thus, the anti-P-selectin antibody significantly blocked adherence of PMNs to ischemia reperfusion-activated cat coronary endothelium. ACh A23187
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In vitro addition ofmAb PB1.3 on PMN adherence to coronary endothelium in nonischemic control cats. To further examine the effect of mAb PB 1.3 on PMN adherence to endothelial cells, we observed the effects of in vitro administration of mAb PB 1.3 on PMN adherence to coronary artery endothelium. To upregulate P-selectin on the endothelial surface, we stimulated the coronary vascular endothelium with thrombin (2 U/ml) for 10 min (4). Addition of mAb PB 1.3 inhibited PMN adherence to thrombin stimulated endothelium in a concentration dependent manner (Fig. 5) . At a concentration of 20 ,g/ml, a maximal inhibitory effect was obtained (-80%). Increasing the concentration ofmAb PB 1.3 did not attenuate PMN adherence any further. Fig. 6 A summarizes the results obtained from 10 to 13 coronary artery ring segments. Very few PMNs adhered to nonstimulated endothelium whereas large numbers of PMNs adhered to endothelium stimulated with thrombin. Addition of mAb PB 1.3 significantly attenuated PMN adherence to the coronary endothelium while the nonblocking antibody (i.e., mAb NBP1.6) had no effect. Similar results were found when endothelial cells were incubated with histamine ( 10 M) for 10 min, another agonist that upregulates P-selectin on the endothelial surface (4). Again, mAb PB 1.3 significantly attenuated PMN adherence to histamine stimulated endothelial cells whereas mAb NBP1.6 had no effect (Fig. 6 B) regulated in coronary vessel endothelial cells after 90 min of ischemia and 20 min of reperfusion. To determine whether P-selectin upregulation after 90 min ofischemia and 20 min of reperfusion plays an important role in PMN adherence to coronary artery endothelium, we examined the ability of mAb PB 1.3 to attenuate this response in ischemic-reperfused coronary arteries. Fig. 7 summarizes the results of 7-10 coronary artery segments taken from three different cats. After 90 min of ischemia and 20 min ofreperfusion, unstimulated PMN adherence to coronary artery endothelium was significantly increased, and this increased adhesiveness was significantly (P < 0.01) inhibited by 20 sg/ml of mAb PB1.3, the same concentration of mAb PB1.3 that inhibited PMN adherence to thrombin and histamine stimulated endothelial cells. In contrast, mAb NBP1.6 did not have any effect on PMN adherence to the ischemic-reperfused endothelial cells. These results confirm that P-selectin, expressed by endothelial cells after ischemia reperfusion, contributes significantly to the interaction between PMNs and endothelium. clearly demonstrate that PB 1.3 reacts with thrombin activated cat platelets. Platelet aggregation. Platelet aggregation to 0.1 U/ml of thrombin was 94±2% of maximum (i.e., 100% light transmittance) in washed cat platelets (n = 4). Addition of40 ,ug/ml of either PB 1.3 or NBP1.6 had no significant effect on cat platelet aggregation to thrombin. Specifically, PB 1.3 inhibited thrombin induced aggregation by 2.3±2.1% (NS) and NBP1.6 inhibited aggregation by 1.1±1.5% (NS). In contrast, 40 ng/ml of taprostene, a prostacyclin analog with antiaggregatory activity, inhibited thrombin induced aggregation by 88±5% (P < 0.01 ). Thus, PB 1.3 does not appear to exert significant antiplatelet activity in feline platelets. Discussion P-selectin, also known as granule membrane protein-140, is one of three membrane glycoproteins in the selectin family of adhesion molecules that regulates interactions of leukocytes with the blood vessel wall ( 18 ) . However, its potential role in pathophysiologic conditions is unclear since there have been very few in vivo studies that examine the role of P-selectin in -p<0.01 NS --p<0.01 80- acute inflammation. The data obtained in this study provide striking evidence that intracellular expression of P-selectin in endothelial cells is markedly upregulated after 90 min of myocardial ischemia and 20 min of reperfusion in the cat. This substantiates earlier in vitro work demonstrating that P-selectin plays a significant role in PMN recruitment in inflammatory states (4, 11) . Moreover, we found that a monoclonal antibody to P-selectin (mAb PB1.3) preserves ischemic-reperfused myocardium by -60% compared to cats given a nonblocking antibody to P-selectin (mAb NBP1 .6). Furthermore, the amount of ischemic myocardium that evolved into necrotic tissue in cats given mAb NBP 1.6 was comparable to our most recent study that used 0.9% NaCl as a vehicle control ( 19) , indicating that mAb NBP 1.6 did not have any detectable effect on infarct size. It is unlikely that the cardioprotective actions of mAb PB1.3 were caused by differing degrees of ischemic injury between the two MI + R groups since collateral flow to ischemic cat myocardium is only 5-7% of initial coronary flow ( 15, 20) and both ischemic groups exhibited comparable ST segment elevation and areas at risk of the left ventricle. Since mAb PB1.3 was administered for only the last 10 minutes of the 90-min ischemic period, decreases in ischemic severity because of a direct effect of mAb PB 1.3 on collateral flow are also unlikely. In addition, mAb PB 1.3 did not significantly alter the pressure rate index, and thus did not alter myocardial oxygen demand. PB1.3 was therefore comparable to recent studies from our laboratory, which used R 15.7, an mAb against CD 18, in MI + R cats ( 15) . Thus, one cannot attribute the cardioprotective effects of mAb PB 1.3 to either alterations in myocardial oxygen supply or demand.
The myocardial salvage afforded by mAb PB 1.3 is most likely caused by its anti-PMN effects in that it decreases PMN adhesion to ischemic-reperfused coronary endothelium. There is substantial evidence demonstrating that PMNs are one ofthe main contributors to myocardial injury associated with ischemia and reperfusion (21) (22) (23) . In support of this, experiments designed to deplete neutrophils (21 ) have been shown to limit myocardial ischemia and reperfusion injury in the dog. Moreover, previous work from our laboratory ( 15) has demonstrated that a monoclonal antibody directed against CD1 8 of the neutrophil decreases myocardial necrosis and also attenuates endothelial dysfunction associated with reperfusion injury. Similarly, Perry and Granger (24) found that neutralization ofCD 18 on cat neutrophils significantly decreased neutrophil adherence and emigration in splanchnic ischemia and reperfusion. Thus, neutrophils play a significant role in myocardial ischemia and reperfusion, and inhibition of P-selectin should decrease neutrophil-endothelial interactions thereby attenuating myocardial necrosis.
The adhesive interaction between PMNs and the endothelium can be rapidly induced and is associated with a time dependent expression ofadhesion molecules that target PMNs to the endothelial cell membrane (1). P-selectin, which is normally present in the Weibel-Palade bodies of endothelial cells, is rapidly translocated to the cell membrane upon stimulation with thrombin, histamine, or oxygen-derived free radicals, where it tethers PMNs to the endothelial cell surface (4, 11) . Since ischemia reperfusion results in the elaboration of a variety of humoral mediators, P-selectin should be expressed within minutes after the onset of reperfusion. Our results provide direct evidence that P-selectin is expressed intracellularly within arterial and venular endothelial cells within 20 min of reperfusion. Because our immunohistochemical method revealed cytoplasmic staining, we were unable to distinguish surface expression of P-selectin. However, at 270 min after reperfusion, we did not observe any immunohistochemical evidence of P-selectin expression in coronary endothelial cells, consistent with Palluy et al. (25) , who found that endothelial cells exposed to hypoxia and reoxygenation expressed P-selectin after 20 min but not 240 min of reoxygenation. Therefore, our results suggest that P-selectin expression on the endothelial cell surface was early and transient after ischemia and reperfusion. Furthermore, we demonstrated that coronary artery endothelium stimulated by ischemia reperfusion, thrombin, or histamine exhibited comparable increases in PMN adherence, a process which mAb PB 1.3 significantly inhibited. Based on these results, one can conclude that P-selectin is an important adhesion molecule regulating PMN adhesion to ischemic-reperfused endothelium.
The PMN ligand to P-selectin is not known with certainty, but some recent evidence suggests that it is an L-selectin associated oligosaccharide, specifically sialyl Lewisx (26, 27) . However, other evidence points to a Ca2' dependent ligand for P-selectin that is distinctly different from L-selectin (28) . Although the exact ligand for P-selectin remains to be elucidated, P-selectin undoubtedly plays a significant role in trafficking of PMNs to the endothelial cell surface.
Targeting of PMNs to the endothelial cell surface allows PMNs to be activated, thereby shedding L-selectin and upregulating CDl 1 /CD1 8 on the PMN plasma membrane (29) . One humoral mediator, platelet activating factor (PAF), is known to increase following ischemia and reperfusion, and facilitates the shedding of L-selectin via its receptor on neutrophils ( 19, 30) . Recent observations by Patel et al. (31) have demonstrated that oxidant injury to the endothelium also stimulates neutrophils through a PAF receptor except that an oxidized phospholipid, rather than native PAF, may be the relevant molecular species in this case. Whatever the precise mechanism of neutrophil activation, the current report on mAb PB ( 15, 34) . Thus, ifPMNs become activated, significant adhesion to the endothelial surface occurs, which contributes significantly to reperfusion-induced myocardial injury. Presumably, P-selectin upregulation on the endothelial cell surface is a prerequisite for maximal interaction between CDl 1 /CD18 and ICAM-1. Therefore, it is possible that mAb PB1.3 prevents initial targeting ofPMNs to the endothelial cell surface, thereby reducing tight adhesive interaction caused by CDI 1 /CD I 8-ICAM mechanisms.
Trafficking of PMNs to the endothelial cell surface by P-selectin may also result in PMN mediated endothelial injury. Upon activation, PMNs induce significant endothelial dysfunction that is characterized by reduced release of both agonist stimulated and basally released nitric oxide (NO) from endothelial cells (7, 8) . These effects appear to be mediated by superoxide radicals generated by activated PMNs that either inactivate or decrease the synthesis ofNO (35) . Several studies (9, 36) have demonstrated that NO reduces PMN adherence to endothelial cells, suggesting that NO is an important intrinsic modulator of leukocyte adherence. Moreover, NO release is significantly diminished after ischemia and reperfusion and its decreased release is associated with significant myocardial injury (7) (8) (37) (38) . Conversely, if NO release is preserved after reperfusion, cardioprotection occurs characterized by significant reductions in both myocardial tissue injury and PMN adherence to the ischemic-reperfused endothelium (36) . Although no data are currently available, NO may act to attenuate upregulation of P-selectin on the surface of the endothelium. This inhibitory influence could dissipate upon reperfusion when endothelial dysfunction occurs.
In this study, endothelial dysfunction and PMN adherence to the arterial endothelium were significantly attenuated after 90 min of ischemia and 270 min of reperfusion in cats treated with mAb PB1.3 compared to mAb NBP1.6. Thus, mAb PB 1.3 prevents extensive endothelial dysfunction that is normally associated with reperfusion injury, thereby sustaining NO release that may act to retard PMNs from adhering to the endothelial cell surface. Alternatively, sustained P-selectin expression has been demonstrated in endothelial cells exposed to H202 allowing P-selectin to act alone in promoting PMN adhesion ( 11) duction in infarct size after marked platelet depletion (40) (41) (42) . In support ofthis, we found that PB1.3 does not inhibit platelet aggregation induced by thrombin. Platelets, however, can interact with neutrophils via P-selectin expressed on plasma membranes of platelets after activation. PB 1.3 blocks this interaction in human platelets and neutrophils ( 12) , and it may also block cat platelet and neutrophil interaction. In vitro studies have shown that substances released from platelets augment leukocyte adhesiveness (42) (43) (44) . A more recent study, however, found that rolling of leukocytes in vivo is inhibited by activated platelets or damaged vascular cells (45) . Thus, the exact role of platelets in augmenting PMN effects in settings of myocardial ischemia and reperfusion is not known with certainty, but it is unlikely to play a major role in this model of reperfusion injury.
In conclusion, we have demonstrated that significant upregulation of P-selectin occurs in ischemic-reperfused endothelial cells and this increased expression is associated with significant PMN adherence to the endothelium. Moreover, administration ofa monoclonal antibody to P-selectin just before reperfusion significantly attenuated myocardial injury and endothelial dysfunction. To our knowledge, this is the first in vivo study examining the role of P-selectin in ischemia reperfusion injury. These results confirm that PMNs mediate myocardial tissue injury after reperfusion, and in particular, demonstrate that P-selectin plays an important role in modulating PMN-endothelial interactions associated with ischemia reperfusion injury.
